B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, H2 2012

B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, ‘B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, H2 2012′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia. B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for B-Cell Chronic Lymphocytic Leukemia.
- A review of the B-Cell Chronic Lymphocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the B-Cell Chronic Lymphocytic Leukemia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, H2 2012

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
B-Cell Chronic Lymphocytic Leukemia Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for B-Cell Chronic Lymphocytic Leukemia 8
B-Cell Chronic Lymphocytic Leukemia Therapeutics under Development by Companies 10
B-Cell Chronic Lymphocytic Leukemia Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Products under Development by Companies 15
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in B-Cell Chronic Lymphocytic Leukemia Therapeutics Development 17
Genzyme Corporation 17
Abbott Laboratories 18
GTC Biotherapeutics, Inc. 19
Ono Pharmaceutical Co., Ltd. 20
Alexion Pharmaceuticals, Inc. 21
B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
samalizumab - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Campath + Fludara - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
alvocidib - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
alvocidib - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
alvocidib - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
alvocidib - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ABT-263 + Rituximab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Leukapheresis + Fludarabine + Cyclophosphamide + Autologous CD19 Specific T-cell Infusion - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 42
cediranib maleate - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ABT-348 + Azacitidine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ONO-4059 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Anti-CD 19 CAR Autologous PBL - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Drug Profile Updates 47
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Dormant Products 48
B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones 49
Featured News & Press Releases 49
Aug 24, 2012: TG Therapeutics Announces Poster Presentation For Ublituximab At 7th International Workshop On Waldenstrom's Macroglobulinemia 49
Jun 04, 2007: ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial In B-Cell Chronic Lymphocytic Leukemia 49
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

List of Tables
Number of Products Under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2012 8
Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Genzyme Corporation, H2 2012 17
Abbott Laboratories, H2 2012 18
GTC Biotherapeutics, Inc., H2 2012 19
Ono Pharmaceutical Co., Ltd., H2 2012 20
Alexion Pharmaceuticals, Inc., H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 27
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Drug Profile Updates 47
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Dormant Products 48

List of Figures
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2012 8
Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Route of Administration, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Molecule Type, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 27

• Most Effective Treatments For Diabetes
  Diabetes is a chronic metabolic disease leading to high blood sugar because or troubled insulin secretion. There are two types of diabetes – type 1 and type 2. Type 1 or juvenile diabetes causes when the body fails to produce enough insulin. Type 2 on the other hand causes when the body cells have lower [...]
• Importance of Educational Books Publishing
  Education plays a crucial role in overall development of a person and the entire society. Students across the globe and various educational levels depend on study material. Whether they are textbooks, reference books or workbooks, they are in a constant need for systematic educational books. Educational book publishing is a versatile crucial branch of book [...]
• How to Treat Arthritis Effectively ?
  The word arthritis stands for inflammation of joints. It is an umbrella term for over 100 diseases that cause pain, discomfort, disability and several other symptoms amongst individuals. Osteoarthritis is one of the most common types of arthritis, which affects elderly. Several other forms of this disease may affect individuals at a very young age [...]
• Benefits of Set top Boxes Amidst the Wave of Digitization
  A set top unit or box is a useful device that provides content through television sets. Set top box is a term that refers to a device, which is used for broadcasting the content. It is different from the devices that help simple recording of media, such as DVDs. Cable operators and satellite companies provide [...]
• What are the Treatments for Alzheimer’s Disease ?
  Alzheimer’s disease is one of the most common types of dementia. Dementia is the condition defined by significant loss of global cognitive ability in a healthy person. This loss is beyond the normal aging process and it only worsens with the age. Alzheimer’s disease is a serious mental health condition and a progressive brain disease [...]

• Foresight 2020: Network Development in a Multi-Channel World

London, May 24th, 2013 – As the costs of branch banking increased in the 80s and 90s, banks attempted to reduce costs by reliance on centers, mobile and online channels to lower costs and improve service. The digitization of banks …

• Italy Healthcare Industry Regulatory and Reimbursement Landscape

The Italian Pharmaceutical Market has Declined in Value Terms Due to the Introduction of Price Cuts and Increasing Focus on the Usage of Generic Drugs in Order to Rein in Ballooning Healthcare Expenditure   The pharmaceutical market (at the consumer …

• Men’s Health & Midlife Women Consumer Market Research Reports

RnRMarketResearch.com offers new market research reports on masculinity Vs health and midlife women embracing power and avoiding invisibility in global consumer markets.   “Masculinity Vs Health: Challenges and Opportunities” and “Midlife Women: Embracing Power and Avoiding Invisibility in Global Consumer …

• France Healthcare Market Regulatory and Reimbursement Landscape

France has a Mature Healthcare Market as it Offers Universal Public Access to Healthcare Facilities and Insurance. The Increasing Disease Burden and the Launch of New Products will Drive the Growth of the Pharmaceutical Market; however, Increasing Focus on Generics …

• Lebanon Cards and Payments Industry Worth 2.4 Million Cards By 2017

Between 2008 and 2012, Lebanon’s cards industry recorded a CAGR of 4.89% in terms of volume and the total number of cards increased from 1.6 million to 2.0 million. The industry has been forecasted to grow at a CAGR of …

Argentina Pharmaceuticals and Healthcare Report Q3 2013

"...... welldeveloped local manufacturing force and its strategic location mean Argentina remains an appealing prospect. Headline Expenditure Projections: Pharmaceuticals: ARS39.4bn (US$8.7bn) in 2012 to ARS49.4bn (US$8.9bn) in 2013; +25.3% in local ......"

Hong Kong Pharmaceuticals and Healthcare Report Q3 2013

"......increasing openness of the Chinese market, which decreases the necessity for firms to set up bases in Hong Kong. Headline Expenditure Projections ? Pharmaceuticals: HKD10.31bn (US$1.33bn) in 2012 to HKD10.77bn (US$1.39bn) in 2013; +4.5% in local curr......"

New Zealand Pharmaceuticals and Healthcare Report Q3 2013

"......n the country. Headline Expenditure Forecasts ? Pharmaceuticals: NZD1.36bn (US$1.10bn) in 2012 to NZD1.37bn (US$1.06bn) in 2013; +0.5% in local currency and -3.8% in US dollar terms. ? Healthcare: NZD21.22bn (US$17.19bn) in 2012 to NZD21.96bn (US$17......."

Taiwan Pharmaceuticals and Healthcare Report Q3 2013

"......e, the Bureau of National Health Insurance (BNHI) in Taiwan is cracking down on prescription drugs waste by tightening its oversight of prescription drug distribution. Therefore, we envisage that main drivers of the Taiwanese pharmaceutical market de......"

Zambia Pharmaceuticals and Healthcare Report Q3 2013

"...... rarely has access to specialist services. There are also other differences in rural/urban healthcare provision, such as those relating to the drug supply chain, drug quality concerns and a lack of modern healthcare facilities in much of the country......."